Analysis of Postoperative Ocular Surface Changes and Intervention Effect After PPV in MGD Dry Eye Patients

Tianjin Medical University Eye Hospital

Status and phase: Completed; Phase 4

Conditions: Meibomian Gland Dysfunction of Unspecified Eye, Unspecified Eyelid

Treatments: Drug: artificial tear therapy; Procedure: Cleaning, hot compresses and massage of the meibomian gland; Drug: Routine preoperative and postoperative anti-infection therapy

Study type: Interventional

Funder types: Other

Identifiers

NCT05771194

hbj112233

Details and patient eligibility

About

AIM: To observe ocular surface changes after phacovitrectomy in patients with mild to moderate meibomian gland dysfunction (MGD)-type dry eye and track clinical treatment response using a Keratograph 5M and a LipiView interferometer.

METHODS: Forty cases were randomized into control group A and treatment group B; the latter received meibomian gland treatment 3 days before phacovitrectomy and sodium hyaluronate before and after surgery. The average non-invasive tear film break-up time (NITBUTav), first non-invasive tear film break-up time (NITBUTf), non-invasive measured tear meniscus height (NTMH), meibomian gland loss (MGL), lipid layer thickness (LLT) and partial blink rate (PBR) were measured preoperatively and 1 week, 1 month and 3 months postoperatively.

Enrollment: 40 patients

Sex: All

Ages: 50 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of dry eye
• Clinical diagnosis for MGD

Exclusion criteria

• eye trauma or eye surgery within the prior 6 months
• use of drugs that affect tear secretion and the stability of the tear film (including anti-glaucoma drugs, cortisol drugs, etc.) within the prior 6 months
• other diseases that affect the function of the eye surface, such as meibomian gland cysts, blepharitis, eyelid valgus, incomplete closure, chronic tear cystitis, corneal disease, glaucoma, or optic neuropathy
• intraoperative suture fixation or closure of a corneal, conjunctival, or scleral incision
• long-term postoperative intraocular hypertension that could not be controlled easily with oral drugs and required puncture and drainage through the anterior chamber
• postoperative corneal epithelial defects lasting more than 1 week or necessitating the use of contact lenses for treatment
• the need for a second operation during the study follow-up eye trauma or eye surgery within the prior 6 months
• use of drugs that affect tear secretion and the stability of the tear film (including anti-glaucoma drugs, cortisol drugs, etc.) within the prior 6 months
• other diseases that affect the function of the eye surface, such as meibomian gland cysts, blepharitis, eyelid valgus, incomplete closure, chronic tear cystitis, corneal disease, glaucoma, or optic neuropathy
• intraoperative suture fixation or closure of a corneal, conjunctival, or scleral incision
• long-term postoperative intraocular hypertension that could not be controlled easily with oral drugs and required puncture and drainage through the anterior chamber
• postoperative corneal epithelial defects lasting more than 1 week or necessitating the use of contact lenses for treatment
• the need for a second operation during the study follow-up

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

40 participants in 2 patient groups

group A

Experimental group

Description:

Group A received conventional preoperative and postoperative anti-infective therapy.

Treatment:

Drug: Routine preoperative and postoperative anti-infection therapy

group B

Active Comparator group

Description:

On the basis of group A,Group B was given 0.1% sodium hyaluronate eye drops 4 times daily for 3 days before surgery (Jiang Xi, Zhen Shiming Pharmaceutical Co., Ltd.) and 3 months after surgery, and one cleaning, hot compresses and massage of the meibomian gland.

Treatment:

Drug: artificial tear therapy

Procedure: Cleaning, hot compresses and massage of the meibomian gland

Drug: Routine preoperative and postoperative anti-infection therapy